Erastin

For research use only. Not for use in humans.

目录号:S7242

Erastin Chemical Structure

CAS No. 571203-78-6

Erastin是一种ferroptosis激活剂,通过作用于线粒体VDAC而起作用,选择性作用于携带致癌基因RAS的肿瘤细胞。

规格 价格 库存 购买数量  
RMB 647.26 现货
RMB 1199.29 现货
RMB 6303.21 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Erastin发表文献131篇:

产品安全说明书

Ferroptosis抑制剂选择性比较

生物活性

产品描述 Erastin是一种ferroptosis激活剂,通过作用于线粒体VDAC而起作用,选择性作用于携带致癌基因RAS的肿瘤细胞。
靶点
Ferroptosis [1]
体外研究

Erastin选择性致死致癌的Ras突变体细胞系,并触发独特的fe依赖性的称为ferroptosis的非凋亡细胞死亡。[1] [2] Erastin直接结合VDAC2并且使得通过NADH-依赖方式产生ROS导致线粒体损害,在一些表达激活突变的肿瘤细胞中,通过RAS-RAF-MEK途径诱导细胞死亡。[3] 此外,erastin通过诱导ROS介导的CID(胱天蛋白酶非依赖性细胞死亡),强烈增强了野生型EGFR细胞的作用。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human BJeH cells NHjRblZHfW6ldHnvckBie3OjeR?= M{njcFYhcA>? Ml7kTY5lfWO2aX;uJI9nKHKnYXP0bZZmKG:6eXflckB{eGWlaXXzJJBzd2S3Y4Tpc44hcW5iaIXtZY4hSkqnSDDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDSRXMh[W[2ZYKgOkBpenNiYomgSGNHNWKjc3XkJIZtd3diY4n0c41mfHKrYzDhcoFtgXOrcx?= M2XYWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEOyN|IyLz5{MkizNlMzOTxxYU6=
human BJeLR cells M1jKfWN6fG:2b4jpZ:Kh[XO|YYm= MnfKNVAh|ryP NX;we5k4OTJiaB?= MVLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCToVNWiClZXzsd{BmgHC{ZYPzbY5oKFKDUzDHNVJXKG23dHHueEBifCBzMDD1UUBifCBzMjDodpMh[nlidIL5dIFvKGKudXWgd5RicW6rbne= MlvDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6M{KzNlEoRjJ{OEOyN|IyRC:jPh?=
human BJ cells NWjXXVhvTnWwY4Tpc44h[XO|YYm= MXu0MlYh|ryP MWTJcoNz\WG|ZTDpckBqdnS{YXPlcIx2dGG{IH;4bYRifGm4ZTDzdIVkcWW|IHnuJIh2dWGwIFLKJINmdGy|IHX4dJJme3OrbnegWGVTXCxiTGSsJHNVKGGwZDDSRXMhTzF{VjDteZRidnRiZ3Xu[ZMh[2WubIOgZZQhPC54IIXN MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV4OEe0PEc,OTd3Nki3OFg9N2F-
human BJ cells M1z1cWZ2dmO2aX;uJIF{e2G7 NHTyeHM6KM7:TR?= M1nHXGlv\HWldHnvckBw\iClZXzsJIRm[XSqIHnuJIh2dWGwIFLKJINmdGy|IHX4dJJme3OrbnegWGVTXCxiTGSsJHNVKGGwZDDSRXMhTzF{VjDteZRidnRiZ3Xu[ZMh[2WubIOgZZQhQSC3TT6= MnXXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3Nki3OFgoRjF5NU[4O|Q5RC:jPh?=
human BJ cells MlvjSpVv[3Srb36gZZN{[Xl? NWDD[JFXUW6mdXP0bY9vKG:oIHPlcIwh\GWjdHigbY4hcHWvYX6gRmoh[2WubIOg[ZhxemW|c3nu[{BVTVKWLDDMWEwhW1RiYX7kJHJCWyCJMULWJI12fGGwdDDn[Y5meyCrbjDwdoV{\W6lZTDv[kBWODF{NjDifUB1enmyYX6gZox2\SCneHPseZNqd25ibXX0bI9lNCCLQ{WwQVMyNjJizszNMi=> M{OxTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NU[4O|Q5Lz5zN{W2PFc1QDxxYU6=
human A673 cells M2fsXmZ2dmO2aX;uJIF{e2G7 NE\J[ZNKdmS3Y4Tpc44hd2ZiY3XscEBl\WG2aDDpckBpfW2jbjDBOlc{KGOnbHzzMEBGSzVyPUOwJO69VS5? MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV4OEe0PEc,OTd3Nki3OFg9N2F-
human MX2 cells MlflSpVv[3Srb36gZZN{[Xl? MmH2TY5lfWO2aX;uJI9nKGOnbHyg[IVifGhiaX6gbJVu[W5iTWiyJINmdGy|LDDFR|UxRTF6IN88UU4> NW\jSJRCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1Olg4PDhpPkG3OVY5PzR6PD;hQi=>
human HOS cells NYPEeZcxTnWwY4Tpc44h[XO|YYm= NW\2[pVXUW6mdXP0bY9vKG:oIHPlcIwh\GWjdHigbY4hcHWvYX6gTG9UKGOnbHzzJEwhTUN3ME2xO{DPxE1w NXLTZVJXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1Olg4PDhpPkG3OVY5PzR6PD;hQi=>
human Hs925.T cells MojzSpVv[3Srb36gZZN{[Xl? NX7N[|UxUW6mdXP0bY9vKG:oIHPlcIwh\GWjdHigbY4hcHWvYX6gTJM6OjVwVDDj[YxteyxiRVO1NF0yPyEQvF2u M3rUNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NU[4O|Q5Lz5zN{W2PFc1QDxxYU6=
human Hs51.T cells M4O1XGZ2dmO2aX;uJIF{e2G7 NF33fVBKdmS3Y4Tpc44hd2ZiY3XscEBl\WG2aDDpckBpfW2jbjDId|UyNlRiY3XscJMtKEWFNUC9NVIh|ryPLh?= MnGzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3Nki3OFgoRjF5NU[4O|Q5RC:jPh?=
human EWS502 cells NGXueHBHfW6ldHnvckBie3OjeR?= MXnJcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCrbjDoeY1idiCHV2O1NFIh[2WubIOsJGVEPTB;MUCg{txONg>? NEnxSFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W2PFc1QCd-MUe1Olg4PDh:L3G+
human BJ cells NHzqUllHfW6ldHnvckBie3OjeR?= MWPJcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCrbjDUSXJVKGW6cILld5NqdmdiaIXtZY4hSkpiY3XscJMtKEWFNUC9NVAh|ryPLh?= NHvoUYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W2PFc1QCd-MUe1Olg4PDh:L3G+
human TC71 cells MlniSpVv[3Srb36gZZN{[Xl? MlO4TY5lfWO2aX;uJI9nKGOnbHyg[IVifGhiaX6gbJVu[W5iVFO3NUBk\WyuczygSWM2OD1zMDFOwG0v MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV4OEe0PEc,OTd3Nki3OFg9N2F-
human U937 cells Ml\DSpVv[3Srb36gZZN{[Xl? M1H4Smlv\HWldHnvckBw\iClZXzsJIRm[XSqIHnuJIh2dWGwIGW5N|ch[2WubIOsJGVEPTB;MUCg{txONg>? MmrrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3Nki3OFgoRjF5NU[4O|Q5RC:jPh?=
human SK-N-MC cells M3vqWmZ2dmO2aX;uJIF{e2G7 NUT4PWpWUW6mdXP0bY9vKG:oIHPlcIwh\GWjdHigbY4hcHWvYX6gV2suVi2PQzDj[YxteyxiRVO1NF0yOCEQvF2u NVzxdJdLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1Olg4PDhpPkG3OVY5PzR6PD;hQi=>
human TC32 cells MW\GeY5kfGmxbjDhd5NigQ>? NXHpPGV6UW6mdXP0bY9vKG:oIHPlcIwh\GWjdHigbY4hcHWvYX6gWGM{OiClZXzsdy=> NEjjO5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W2PFc1QCd-MUe1Olg4PDh:L3G+
human U2OS cells MWrGeY5kfGmxbjDhd5NigQ>? NGjkdllKdmS3Y4Tpc44hd2ZiY3XscEBl\WG2aDDpckBpfW2jbjDVNm9UKGOnbHzzMEBGSzVyPU[g{txONg>? MoCzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3Nki3OFgoRjF5NU[4O|Q5RC:jPh?=
human LNCaP cells M{SzTGZ2dmO2aX;uJIF{e2G7 NVHZXlZPUW6mdXP0bY9vKG:oIHPlcIwh\GWjdHigbY4hcHWvYX6gUG5E[VBiY3XscJMtKEWFNUC9OkDPxE1w NYXQPY82RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1Olg4PDhpPkG3OVY5PzR6PD;hQi=>
human Calu1 cells MkjzSpVv[3Srb36gZZN{[Xl? M2nSeWlvcGmkaYTpc44hd2ZiaIXtZY4hS2GudUGgZ4VtdHNiZYjwdoV{e2mwZzDLVmFUKHerdHigZYN1cX[jdHnu[{BufXSjdHnvcpMh[nlidIL5dIFvKGKudXWg[ZhkdHW|aX;uJIF{e2G7LDDJR|UxRTRizszNMi=> M3LMXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NU[4O|Q5Lz5zN{W2PFc1QDxxYU6=
human SKUT cells MUHGeY5kfGmxbjDhd5NigQ>? MkfDTY5lfWO2aX;uJI9nKGOnbHyg[IVifGhiaX6gbJVu[W5iU1vVWEBk\WyuczygSWM2OD12IN88UU4> NGHo[|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W2PFc1QCd-MUe1Olg4PDh:L3G+
human MES-SA cells MlPTSpVv[3Srb36gZZN{[Xl? NVjZdlRZUW6mdXP0bY9vKG:oIHPlcIwh\GWjdHigbY4hcHWvYX6gUWVUNVODIHPlcIx{NCCHQ{WwQVMh|ryPLh?= NUfve3l[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1Olg4PDhpPkG3OVY5PzR6PD;hQi=>
human SVR cells MYfGeY5kfGmxbjDhd5NigQ>? MUfJcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCrbjDoeY1idiCVVmKgZ4VtdHNuIFXDOVA:Oi53IN88UU4> NWj2UplvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1Olg4PDhpPkG3OVY5PzR6PD;hQi=>
human HT1080 cells Mn;HSpVv[3Srb36gZZN{[Xl? NGDJUoFKdmS3Y4Tpc44hd2ZiY3XscEBl\WG2aDDpckBpfW2jbjDIWFExQDBiY3XscJMhcW5icILld4Vv[2Vib3[gVGQuQThyNUmgZpkhfHK7cHHuJIJtfWViZYjjcJV{cW:wIH3leIhw\CxiSVO1NF0yKM7:TT6= MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV4OEe0PEc,OTd3Nki3OFg9N2F-
human BJ cells M4XUVWZ2dmO2aX;uJIF{e2G7 M2e0S2lv\HWldHnvckBw\iClZXzsJIRm[XSqIHnuJIh2dWGwIFLKJINmdGy|IHX4dJJme3OrbnegWGVTXCxiTGSsJHNVKGGwZDDSRXMhTzF{VjDteZRidnRiZ3Xu[ZMh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiUFStPVgxPTliYomgeJJ6eGGwIHLseYUh\XilbIXzbY9vKG2ndHjv[EwhUUN3ME2wMlkh|ryPLh?= NEjUU5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W2PFc1QCd-MUe1Olg4PDh:L3G+
human HeLa cells NHH4XoxHfW6ldHnvckBie3OjeR?= MkXsTY5lfWO2aX;uJI9nKGOnbHyg[IVifGhiaX6gbJVu[W5iSHXMZUBk\WyuczygSWM2OD1yLk[g{txONg>? MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV4OEe0PEc,OTd3Nki3OFg9N2F-
human CCF-STTG1 cells NI[5TFhHfW6ldHnvckBie3OjeR?= M{foR2lvcGmkaYTpc44hd2ZiWHP0JIlvKGi3bXHuJGNETi2VVGTHNUBk\WyuczDhd5Nme3OnZDDhd{BodHW2YX3heIUhemWuZXHz[UBi\nSncjCyJIhzeyCkeTDmcJVwem:vZYTyfUwhUUN3ME2wMlIh|ryPLh?= NWLTcmJ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yN|EyPTZpPkK2NlMyOTV4PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
HSPA5 / p-EIF2AK3; 

PubMed: 28130223     


Western blot analysis indicated protein expression in PDAC cells following treatment with erastin (2.5-40 μM) for 24 hours (n=3, *p < 0.05 versus untreated group). 

TfR1 / p-JNK / JNK / p-P38; 

PubMed: 31105999     


HL-60/NRAS (Q61L) cells were treated with erastin (5 μM) combined with SP600125 (10 μM) and SB202190 (10 μM) for 48 h. TfR1 expression and the phosphorylation of p38 (p-P38) and JNK1/2 (p-JNK1/2) were assayed by western blot. 

GPX4 / cleaved-PARP / cleaved-caspase3 / LC3 / p62 / LDH / HMGB1; 

PubMed: 27308510     


HL-60 and Jurkat cells were treated with erastin (5 μM) for 24 h and subjected to western blot analysis of the indicated proteins in whole cell extracts or supernatant. 

GRP78; 

PubMed: 29383150     


Cells were treated with 50 μM erastin for various time(1-24 h). Whole-cell extracts were analyzed with immunoblotting assay.

28130223 31105999 27308510 29383150
Growth inhibition assay
Cell survival; 

PubMed: 29348676     


The A375 and G-361 human melanoma cells were treated with erastin (2.5-40 µM) or RSL3 (0.1-10 µM) with or without a cell death inhibitor (ferrostatin-1, 1 µM; ZVAD-FMK, 10 µM; necrosulfonamide, 0.5 µM) for 24 h. Cell death was assayed using a CCK-8 kit. Data shown represent mean ± SD from three independent experiments. ****p < 0.0001.

29348676
Immunofluorescence
HMGB1; 

PubMed: 31105999     


HL-60/NRAS (Q61L) cells were treated with erastin (5 μM) with or without Fer-1 (1 μM) pretreatment for 48 h, and then the nuclear/cytosolic HMGB1 expression was assayed by immunofluorescence(Green, HMGB1; blue, nucleus). 

31105999

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[1]
- 合并
  • Cell lines: BJ-TERT/LT/ST/RASV12细胞
  • Concentrations: 5 or 10 μg/mL
  • Incubation Time: 6-11小时
  • Method: BJ-TERT/LT/ST/RASV12细胞接种在100 mm平皿中,并使其生长过夜。细胞用erastin(5或10微克/毫升)处理6,8,或11小时。camptothecin处理(0.4微克/毫升)的对照被维持,在接种的时候处理20小时。处理后,细胞用胰蛋白酶/EDTA孵育并用含血清的新鲜培养基洗1次,然后用磷酸盐缓冲盐水洗涤两次。细胞同1×结合缓冲液重悬。100 μL重悬细胞在5μL的膜联蛋白V-FITC和碘化丙啶iodiode在黑暗中孵育15分钟。然后加入400 μl的1×结合缓冲液S并用流式细胞仪分析。采集数据,并使用CellQuest软件进行分析。只有不被碘化丙啶染色的活细胞使用FL1通道的膜联蛋白V-FITC染色分析。
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 19 mg/mL (34.73 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5%DMSO+40%PEG 300+5%Tween80+ddH2O
1.75mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 547.04
化学式

C30H31ClN4O4

CAS号 571203-78-6
储存条件 3年 -20°C 粉状
1个月 -80°C 溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
Tags: 购买Erastin | Erastin供应商 | 采购Erastin | Erastin价格 | Erastin生产 | 订购Erastin | Erastin代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID